Issue link: https://beckershealthcare.uberflip.com/i/981659
68 Executive Briefing This antimicrobial effect lasts throughout the seven-day recommended wear time and provides a minimum of four- log reduction against a wide variety of clinically relevant microorganisms for up to seven days. The antimicrobial action is also rapid; ReliaTect® Post-Op Dressing with CHG reduces 99.99 percent of clinically relevant bacteria within one day. 18 In addition to its antimicrobial benefits, the acrylic adhesive is absorptive. The dressing can absorb light to moderate amounts of blood, perspiration and exudates, but is not designed for large amounts of fluid absorption. ReliaTect® Post-Op Dressing with CHG is transparent, providing visualization of the surgical wound site for inspection and assessment; this feature may reduce the need for dressing changes and associated costs. Transparency helps facilitate daily, direct observation of the surgical site, which is the "gold standard" for SSI detection. 19 The dressing is breathable, allowing for oxygen and moisture vapor exchange, yet is impermeable to external contaminants. The vapor transmission rate is greater than the absorption rate, and this dynamic moisture management can help the dressing to remain securely adhered in the presence of exudate and other fluids. 18 ReliaTect® Post-Op Dressing with CHG has a wear time of up to seven days, minimizing the need for dressing changes. 18 It is noncytotoxic, non-irritating to the skin, and the material is flexible, providing skin-friendly contact that conforms to bodily contours. ReliaTect® Post-Op Dressing with CHG is offered in two sizes to accommodate different surgical wound sizes: 8 cm x 15 cm (3.2 in x 5.9 in) and 10 cm x 25 cm (3.9 in x 9.8 in). n References 1. Magill, S. S., Edwards, J. R., Bamberg, W., et al. (2014) Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team. Multistate point-prevalence survey of health care-associated infections. N Engl J Med, 370(13), 1198-1208. doi:10.1056/ NEJMoa1306801. 2. Kirkland, K. B., Briggs, J. P., Trivette, S. L., Wilkinson, W. E., & Sexton, D. J. (1999). The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs. Infect Control Hosp Epidemiol, 20(11), 725-730. doi:10.1086/501572 3. Digiovine, B., Chenoweth, C., Watts, C., & Higgins, M. (1999). The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit. Am J Respir Crit Care Med, 160(3), 976-981. doi:10.1164/ ajrccm.160.3.9808145 4. Cai, J., Karam, J. A., Parvizi, J., Smith, E. B., & Sharkey, P. F. (2014). Aquacel surgical dressing reduces the rate of acute PJI following total joint arthroplasty: a case- control study. J Arthroplasty, 29(6), 1098-1100. doi:10.1016/j.arth.2013.11.012 5. Ban, K. A., Minei, J. P., Laronga, C., et al. (2017). American College of Surgeons and Surgical Infection Society: Surgical Site Infection Guidelines, 2016 Update. J Am Coll Surg, 224(1), 59-74. doi:10.1016/j.jamcollsurg.2016.10.029 6. Centers for Medicare & Medicaid Services. (2015). Hospital-Acquired Conditions. Available at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ HospitalAcqCond/Hospital-Acquired_Conditions.html 7. Office of Disease Prevention and Health Promotion. Health care quality and patient safety overview. Available at: https://health.gov/hcq/prevent-hai.asp 8. The Joint Commission. The Joint Commission's Implementation Guide for NPSG.07.05.01 on Surgical Site Infections: The SSI Change Project. Available at: https://www.jointcommission.org/assets/1/18/Implementation_Guide_for_NPSG_ SSI.pdf 9. Mangram, A. J., Horan, T. C., Pearson, M. L., Silver, L. C., & Jarvis, W. R. (1999). Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control, 27(2), 97-132. 10. Bashir, M. H., Olson, L. K., & Walters, S. A. (2012). Suppression of regrowth of normal skin flora under chlorhexidine gluconate dressings applied to chlorhexidine gluconate-prepped skin. Am J Infect Control, 40(4), 344-348. doi:10.1016/j. ajic.2011.03.030 11. National Collaborating Centre for Women's and Children's Health. (2008). Surgical Site Infection: Prevention and Treatment of Surgical Site Infection. Available at: https://www.nice.org.uk/guidance/cg74 12. Abboud, E. C., Settle, J. C., Legare, T. B., Marcet, J. E., Barillo, D. J., & Sanchez, J. E. (2014). Silver-based dressings for the reduction of surgical site infection: review of current experience and recommendation for future studies. Burns, 40 Suppl 1, S30-S39. doi:10.1016/j.burns.2014.09.011 13. Edmiston CE Jr, Bruden B, Rucinski MC, Henen C, Graham MB, Lewis BL. Reducing the risk of surgical site infections: does chlorhexidine gluconate provide a risk reduction benefit? Am J Infect Control. 2013;41(5 Suppl):S49-55. doi: 10.1016/j.ajic.2012.10.030. Review. PubMed PMID: 23622749. 14. Schweizer, M. L., Chiang, H. Y., Septimus, E., et al. (2015). Association of a bundled intervention with surgical site infections among patients undergoing cardiac, hip, or knee surgery. JAMA, 313(21), 2162-2171. doi:10.1001/ jama.2015.5387 15. Dumville, J. C., Gray, T. A., Walter, C. J., et al. (2016). Dressings for the prevention of surgical site infection. Cochrane Database Syst Rev, 12, CD003091. doi:10.1002/14651858.CD003091.pub4. 16. British Medical Association and Royal Pharmaceutical Society of Great Britain. (2011). British National Formulary (BNF): Appendix 8: wound management products and elasticated garments. Available at: https://www.bnf.org/products/ bnf-online/ 17. Goldman, M.P., Fronek, A. (1992). Consensus Paper on Venous Leg Ulcer. The Journal of Dermatologic Surgery and Oncology, 18(7), 592-602. doi:10.1111/j.1524-4725.1992.tb03513.x 18. Eloquest Healthcare. (2016). ReliaTect® Post-Op Dressing with CHG Instructions for Use. Data on file. 19. Anderson, D. J., Podgorny, K., Berrios-Torres, S. I., et al. (2014). Strategies to prevent surgical site infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol, 35(6), 605-627. doi: 10.1086/676022 MTR-MKT-000345-A Eloquest Healthcare, Inc. is a wholly owned subsidiary of Ferndale Pharma Group, Inc. that is focused specifically on serving hospitals, their clinicians, and patients. We collaborate with our customers to deliver safer, more compassionate care. Eloquest Healthcare's products support strategies that prevent hospital acquired infections and provide better outcomes, higher quality and lower healthcare costs. More information can be found at www.eloquesthealthcare.com. C M Y CM MY CY CMY K